NASH trials will often use the criteria proposed by the NASH Clinical Research Network (NASH-CRN), the NAS scoring system, to classify patients as suitable for study enrolment. NASummation of the histology scores for fat (0-3), inflammation (0-3), and ballooning (0-2) with a score of 4 or 5 or higher regarded as NASH. Whilst the score doesn't includebrosis, the rapidly evolving clinical trials landscape in NASH has seen a shift in emphasisdrugs proposed to target liver fat to the targeting of fibrosis. This was due tobservations contrary to the previously held belief that fibrosis could not improve, and the data to support fibrosis being predictive of clinical outcomes. As a result, many clinicalw require patients to have a NAS ≥4 or 5, with the regulatory accepted criteriaquirement for at least a score of 1 for inflammation and 1 for ballooning, and evidence ofbrosis of stage 2 or more (scored using the Kleiner-Brunt (0-4) scale). The route by whichver biopsy is indicated for inclusion to a clinical trial is usually based on patientd clinical work-up. In the Primary care patient presents with clinical riskASH like metabolic syndrome. Blood biomarkers will be checked and if raisedwill be referred to the hepatology. In the secondary care patient might have agraphy and if CAP is equal or more than 280 and LSM is equal or more than 7 kPa, patient will have biopsy.

However clinical risk factors are often not sensitive enough, and NASH trials often sufferhigh levels of screen fails at biopsy, meaning a large proportion are unnecessarily biopsied. Screening strategies are becoming increasingly more popular in order to reduce theumber that fail screening and metrics derived from magnetic resonance imaging (MRI) such as T1-mapping and PDFF are emerging as promising diagnostic screening biomarkers in NASH.

MRI exploits the magnetic properties of hydrogen nuclei protons within a determined magneticd. T1 mapping measures longitudinal relaxation time, a measure of how long it takes forquilibrate their spins to the magnetic field after being excited by adiofrequency pulse, and thus is an indicator of regional tissue water (proton) content. T1g has shown promise as an effective biomarker of liver inflammation and fibrosis, as T1gthens with increases in extracellular fluid (which may be caused bybrosis and/or inflammation). The presence of iron however, which can be accurately measuredRI-T2star (T2*) relaxation time, shortens the T1, and thus must be accounted for. Angorithm has been created (Perspectum Diagnostics) that allows for the bias introduced byvated iron to be removed from the T1 measurements, yielding the iron corrected T1 (cT1).d T1 (cT1) has been shown to correlate with fibro-inflammatory disease and canvely stratify patients with NASH and cirrhosis (7).

MRI-PDFF is a ratio, expressed as a percentage, of the fraction of the MRI-visible protonsbutable to fat divided by all MRI-visible protons in that region of the liverbutable to fat and water. Taking advantage of the chemical shift between fat and water,ulse sequences including fast spin echo and gradient-recalled echo (GRE) sequences can be used to acquire images at multiple echo times at which fat and water signals have differenthases relative to each other. PDFF has been shown to have excellent correlation between histologically graded steatosis across the clinical range seen in NASH and high diagnosticuracy in stratification of all grades of liver steatosis, although it is weaker in thedvanced fibrosis. Whilst PDFF does not correlate with other features of NASH, it has been reported that NAFLD patients with grade one steatosis are more likely to haveharacteristics of advanced liver disease such as fibrosis and ballooning, and changes in hepatic steatosis may be correlated with changes in other histological endpoints. Thus whilstuthors advise caution about using PDFF as a biomarker of NASH it has been well accepted by the NASH community as a biomarker for both enrolment and as an endpoint in NASH clinical(e.g. MOZART: NCT01766713; FLINT: NCT01265498).

Where cT1 appears to have an advantage over PDFF as a non-invasive biomarker for NASH, is in detection of patients with both disease activity (ballooning and inflammation) and fibrosisT1 has been reported to be correlated with ballooning, fibrosis and NAFLD activity score,d has been shown to predict clinical outcomes. As such it is emerging as a promising biomarker for both screening and as an endpoint in NASH clinical trials (NCT02421094;CT02912260) particularly those investigating mechanisms of action of fibro-inflammation, ordistinguishing those with more advanced NASH with fibrosis. Both cT1 and PDFF can bequired as part of the LiverMultiScan™ (LMS) imaging protocol (Perspectum Diagnostics Ltd,K).

Based on the data reported in the literature, and from our preliminary analysis of N=109 biopsy-confirmed NAFL patients recruited from the two UK studies, both cT1 and PDFF appear to have potential to become diagnostic biomarkers, that may have utility for clinical trialulation enrichment when used in conjunction with clinical risk factors. Specifically, for PDFF to identify participants who are more likely to have histopathologic findings ofd cT1 to identify participants who are more likely to have histopathologicdings of NASH, and NASH with fibrosis.

The primary objective of this study is to evaluate cT1 (Corrected T1) as a diagnostic biomarker that can be used, in conjunction with clinical risk factors, to identify patients who are more likely to have liver histopathologic findings of non-alcoholic steatohepatitis (NASH). Ideally, this biomarker should identify patients with a non-alcoholic fatty liver disease activity score (NAS) ≥ 4 and liver fibrosis (NASH/CRN Brunt/Kleiner scale) ≥ stage 2histopathologic assessment.

Based on our observations from earlier trials, our hypothesis is that we expect cT1 to have good diagnostic accuracy for discriminating those with NAS≥4 & F≥2 from those without